Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1994 Sep;113(1):129–136. doi: 10.1111/j.1476-5381.1994.tb16184.x

Effects of chronic infusions of alpha-trinositol on regional and cardiac haemodynamics in conscious rats.

S M Gardiner 1, P A Kemp 1, B Fallgren 1, T Bennett 1
PMCID: PMC1510081  PMID: 7812602

Abstract

1. Male, Long Evans rats (350-450 g) were chronically instrumented for the measurement of renal, mesenteric and hindquarters haemodynamics, and were given three consecutive, 24 h infusions of vehicle (sterile saline at 0.3 ml h-1, n = 8) or alpha-trinositol (D-myo-inositol-1,2,6-triphosphate) at 5, 20 and 80 mg kg-1 h-1 (0.3 ml h-1; n = 9). During infusion of alpha-trinositol at 5 or 20 mg kg-1 h-1, cardiovascular changes were little different from those seen during saline infusion. However, during infusion of alpha-trinositol at 80 mg kg-1 h-1 there were increases in hindquarters vascular conductance, renal flow and vascular conductance, that were all significantly different from the changes seen in the saline group. Infusion of alpha-trinositol at the high dose in naive rats (n = 8) had even more marked vasodilator effects. 2. Two groups of rats (n = 8 in each), chronically instrumented for the measurement of cardiac haemodynamics, were given 48 h infusions of saline (0.3 ml h-1) or alpha-trinositol (2 mg kg-1 bolus, 80 mg kg-1 h-1 infusion at 0.3 ml h-1). During the infusion of saline, there were slight reductions in heart rate, cardiac index, peak aortic flow, dF/dtmax and central venous pressure. In the animals receiving alpha-trinositol, with the exception of central venous pressure, all the above variables, together with total peripheral conductance, increased. 3. These results, collectively, indicate that incremental infusions of alpha-trinositol do not reveal its full vasodilator potential, possibly due to concurrent activation of counter-regulatory vasoconstrictor mechanisms.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
129

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adamsson M., Edvinsson L. Blockade of neuropeptide Y-induced potentiation of noradrenaline-evoked vasoconstriction by D-myo-inositol-1.2.6-trisphosphate (PP56) in rabbit femoral arteries. Neuropeptides. 1991 May;19(1):13–16. doi: 10.1016/0143-4179(91)90068-t. [DOI] [PubMed] [Google Scholar]
  2. Carrington A. L., Calcutt N. A., Ettlinger C. B., Gustafsson T., Tomlinson D. R. Effects of treatment with myo-inositol or its 1,2,6-trisphosphate (PP56) on nerve conduction in streptozotocin-diabetes. Eur J Pharmacol. 1993 Jun 24;237(2-3):257–263. doi: 10.1016/0014-2999(93)90277-o. [DOI] [PubMed] [Google Scholar]
  3. Donoso M. V., Boric M., Prado M., Fournier A., St Pierre S., Edvinsson L., Huidobro-Toro J. P. D-myo-inositol 1,2,6-trisphosphate blocks neuropeptide Y-induced facilitation of noradrenaline-evoked vasoconstriction of the mesenteric bed. Eur J Pharmacol. 1993 Aug 10;240(1):93–97. doi: 10.1016/0014-2999(93)90552-s. [DOI] [PubMed] [Google Scholar]
  4. Edvinsson L., Adamsson M., Jansen I. Neuropeptide Y antagonistic properties of D-myo-inositol-1.2.6-trisphosphate in guinea pig basilar arteries. Neuropeptides. 1990 Oct;17(2):99–105. doi: 10.1016/0143-4179(90)90056-5. [DOI] [PubMed] [Google Scholar]
  5. Edvinsson L., Adamsson M. Neuropeptide Y inhibits relaxation of guinea pig cerebral, coronary, and uterine arteries: blockade by D-myo-inositol-1,2,6-triphosphate. J Cardiovasc Pharmacol. 1992 Sep;20(3):466–472. doi: 10.1097/00005344-199209000-00019. [DOI] [PubMed] [Google Scholar]
  6. Feth F., Erdbrügger W., Rascher W., Michel M. C. Is PP56 (D-myo-inositol-1,2,6-trisphosphate) an antagonist at neuropeptide Y receptors? Life Sci. 1993;52(23):1835–1844. doi: 10.1016/0024-3205(93)90003-l. [DOI] [PubMed] [Google Scholar]
  7. Gardiner S. M., Compton A. M., Bennett T., Hartley C. J. Can pulsed Doppler technique measure changes in aortic blood flow in conscious rats? Am J Physiol. 1990 Aug;259(2 Pt 2):H448–H456. doi: 10.1152/ajpheart.1990.259.2.H448. [DOI] [PubMed] [Google Scholar]
  8. Gardiner S. M., Compton A. M., Bennett T. Regional hemodynamic effects of calcitonin gene-related peptide. Am J Physiol. 1989 Feb;256(2 Pt 2):R332–R338. doi: 10.1152/ajpregu.1989.256.2.R332. [DOI] [PubMed] [Google Scholar]
  9. Gardiner S. M., Compton A. M., Kemp P. A., Bennett T., Foulkes R., Hughes B. Regional haemodynamic effects of prolonged infusions of human alpha-calcitonin gene-related peptide in conscious, Long Evans rats. Br J Pharmacol. 1991 Jun;103(2):1509–1514. doi: 10.1111/j.1476-5381.1991.tb09818.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Gardiner S. M., Compton A. M., Kemp P. A., Bennett T., Hughes B., Foulkes R. Differential effects of (+/-)-dobutamine and human alpha-CGRP on cardiac and on regional haemodynamics in conscious Long Evans rats. Br J Pharmacol. 1991 Jun;103(2):1500–1508. doi: 10.1111/j.1476-5381.1991.tb09817.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Gardiner S. M., Compton A. M., Kemp P. A., Bennett T. Regional and cardiac haemodynamic responses to glyceryl trinitrate, acetylcholine, bradykinin and endothelin-1 in conscious rats: effects of NG-nitro-L-arginine methyl ester. Br J Pharmacol. 1990 Nov;101(3):632–639. doi: 10.1111/j.1476-5381.1990.tb14132.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Gardiner S. M., Kemp P. A., Bennett T. Effects of NG-nitro-L-arginine methyl ester on vasodilator responses to adrenaline or BRL 38227 in conscious rats. Br J Pharmacol. 1991 Nov;104(3):731–737. doi: 10.1111/j.1476-5381.1991.tb12496.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kulka P. J., Tryba M. Inotropic support of the critically ill patient. A review of the agents. Drugs. 1993 May;45(5):654–667. doi: 10.2165/00003495-199345050-00003. [DOI] [PubMed] [Google Scholar]
  14. Pernow J., Modin A., Lundberg J. M. No effect of D-myo-inositol-1,2,6-triphosphate on vasoconstriction evoked by neuropeptide Y and non-adrenergic sympathetic nerve stimulation. Eur J Pharmacol. 1992 Nov 3;222(1):171–174. doi: 10.1016/0014-2999(92)90836-s. [DOI] [PubMed] [Google Scholar]
  15. Potter E. K., Edvinsson L., Gustafsson T. Antagonism of pre- and postjunctional responses to neuropeptide Y and sympathetic stimulation by D-myo-inositol-1,2,6-trisphosphate in the anaesthetised dog. Eur J Pharmacol. 1992 Oct 20;221(2-3):307–314. doi: 10.1016/0014-2999(92)90717-i. [DOI] [PubMed] [Google Scholar]
  16. Ruf J. C., Ciavatti M., Gustafsson T., Renaud S. Effects of PP-56 and vitamin E on platelet hyperaggregability, fatty acid abnormalities, and clinical manifestations in streptozocin-induced diabetic rats. Diabetes. 1991 Feb;40(2):233–239. doi: 10.2337/diab.40.2.233. [DOI] [PubMed] [Google Scholar]
  17. Schwieler J. H., Hjemdahl P. D-myo-inositol-1,2,6-triphosphate (PP56) antagonizes nonadrenergic sympathetic vasoconstriction: possible involvement of neuropeptide Y. J Cardiovasc Pharmacol. 1993 Mar;21(3):347–352. doi: 10.1097/00005344-199303000-00001. [DOI] [PubMed] [Google Scholar]
  18. Sun X. Y., Dahlöf C., Edvinsson L., Hedner T. D-myo-inositol-1,2,6-trisphosphate is a selective antagonist of neuropeptide Y-induced pressor responses in the pithed rat. Eur J Pharmacol. 1991 Nov 12;204(3):281–286. doi: 10.1016/0014-2999(91)90853-i. [DOI] [PubMed] [Google Scholar]
  19. Sun X. Y., Edvinsson L., Hedner T. Effects of d-myo-inositol-1,2,6-trisphosphate on neuropeptide Y-induced potentiation of various vasoconstrictor agents in the rat. J Pharmacol Exp Ther. 1992 Jun;261(3):1147–1152. [PubMed] [Google Scholar]
  20. Sun X. Y., Edvinsson L., Hedner T. Neuropeptide Y-induced pressor responses in spontaneously hypertensive and Wistar-Kyoto rats antagonized by D-myo-inositol-1,2,6-triphosphate (PP56). J Hypertens Suppl. 1991 Dec;9(6):S344–S345. [PubMed] [Google Scholar]
  21. Sun X., Edvinsson L., Hedner T. Cardiovascular effects of alpha-trinositol in spontaneously hypertensive and normotensive Wistar-Kyoto rats. J Hypertens. 1993 Sep;11(9):935–943. doi: 10.1097/00004872-199309000-00007. [DOI] [PubMed] [Google Scholar]
  22. Tarazi R. C., Dustan H. P., Bravo E. L., Niarchos A. P. Vasodilating drugs: contrasting haemodynamic effects. Clin Sci Mol Med Suppl. 1976 Dec;3:575s–578s. doi: 10.1042/cs051575s. [DOI] [PubMed] [Google Scholar]
  23. Theodorsson-Norheim E. Friedman and Quade tests: BASIC computer program to perform nonparametric two-way analysis of variance and multiple comparisons on ranks of several related samples. Comput Biol Med. 1987;17(2):85–99. doi: 10.1016/0010-4825(87)90003-5. [DOI] [PubMed] [Google Scholar]
  24. Trapani A. J., Smits G. J., McGraw D. E., McMahon E. G., Blaine E. H. Hemodynamic basis for the depressor activity of zaprinast, a selective cyclic GMP phosphodiesterase inhibitor. J Pharmacol Exp Ther. 1991 Jul 1;258(1):269–274. [PubMed] [Google Scholar]
  25. Wahlestedt C., Reis D. J., Yoo H., Adamsson M., Andersson D., Edvinsson L. A novel inositol phosphate selectively inhibits vasoconstriction evoked by the sympathetic co-transmitters neuropeptide Y (NPY) and adenosine triphosphate (ATP). Neurosci Lett. 1992 Aug 31;143(1-2):123–126. doi: 10.1016/0304-3940(92)90247-5. [DOI] [PubMed] [Google Scholar]
  26. de Wildt D. J., Sangster B. An evaluation of derived aortic flow parameters as indices of myocardial contractility in rats. J Pharmacol Methods. 1983 Aug;10(1):55–64. doi: 10.1016/0160-5402(83)90014-1. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES